U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. FDA Product-Specific Guidances: Lighting the Development Pathway for Generic Drugs - 05/05/2021 - 05/05/2021
  1. Drugs


Event Title
FDA Product-Specific Guidances: Lighting the Development Pathway for Generic Drugs
May 5, 2021


May 5, 2021
9:00 AM - 12:30 PM ET


Visit CDER Small Business and Industry Assistance Webpage

This webinar is FREE.

FDA will provide an overview of Product-Specific Guidances (PSGs), including how they are developed and revised and their role in facilitating generic drug development and generic drug application review. FDA will also discuss ways prospective and current generic drug applicants can use PSGs, including those for complex products, to improve the efficiency of generic drug development.

This webinar is being offered as part of FDA’s Drug Competition Action Plan, which aims to increase competition and make it easier and more efficient for drug developers to bring more generics into the marketplace, while maintaining FDA’s high standards for quality and scientific rigor.

Learning Objectives

  • Describe general principals of PSGs
  • Discuss the process of how PSGs are developed and revised
  • Describe how FDA communicates current thinking and expectations on how to develop generic drug products therapeutically equivalent to specific reference listed drugs through PSGs
  • Understand how PSGs and other pre-submission communications facilitate generic drug development and generic drug application assessment.

FDA Speakers

Rob Lionberger, Director, ORS/OGD

Lei Zhang, Deputy Director, ORS/OGD

CDR Christine Le, PSG Program Manager (Acting), ORS/OGD

Myong-Jin Kim, Deputy Division Director, Division of Quantitative Methods and Modeling, ORS | OGD

Markham Luke, Division Director, Division of Therapeutic Performance (DTP) | ORS | OGD

Mitchell Frost, Team Lead, DTP | ORS |OGD

Paramjeet Kaur, Staff Fellow, OB/OGD

David Coppersmith, Regulatory Counsel, OGDP/OGD

Intended Audience

Generic drug industry stakeholders including current and potential applicants who are interested in submitting an application for generic drug development.

FDA Resources


Real-time attendance is required for the certificate of attendance which can be used in support of CEs for the following professional organizations. Certificates are only available during the two weeks post-event.
This course:

  • has been pre-approved by RAPS as eligible for credits (appropriate to real-time attendance) towards a participant’s RAC recertification upon full completion.
  • has been pre-approved by SOCRA who accepts documentation of candidate participation in continuing education programs for re-certification if the program is applicable to clinical research regulations, operations or management, or to the candidate's clinical research therapeutic area.
  • has been pre-approved by SQA as eligible for 1 non-GCP or non-GLP unit for every 1 hour of instructional time towards a participant’s RQAP re-registration.
  • has been approved by ACRP for continuing education in clinical research. ACRP will provide 1 ACRP contact hour for every 45-60 minutes of qualified material.


Back to Top